MEPACT

This brand name is authorized in Austria, Brazil, Croatia, Cyprus, Estonia, Finland, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug MEPACT contains one active pharmaceutical ingredient (API):

1	Mifamurtide UNII 1LM890Q4FY - MIFAMURTIDE
	Mifamurtide (MTP-PE) is a fully synthetic derivative of muramyl dipeptide (MDP). MTP-PE is a potent activator of monocytes and macrophages. The exact mechanism by which mifamurtide activation of monocytes and macrophages leads to anti-tumour activity in animals and humans is not yet known.
	Read more about Mifamurtide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEPACT Powder for concentrate for dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AX15	Mifamurtide	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501115020024602
EE	Ravimiamet	1412772
ES	Centro de información online de medicamentos de la AEMPS	08502001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	130982
GB	Medicines & Healthcare Products Regulatory Agency	166991
IL	מִשְׂרַד הַבְּרִיאוּת	6920
IT	Agenzia del Farmaco	039549011
LT	Valstybinė vaistų kontrolės tarnyba	1037114
NL	Z-Index G-Standaard, PRK	102458
PL	Rejestru Produktów Leczniczych	100285212
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54739001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699456790041